Wockhardt UK Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Wockhardt UK Limited Pharmaceutical Import Records from India — 9 Products, $28.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Wockhardt UK Limited — Pharmaceutical Importer Profile (2026) | 9 Products, $28.4M Trade | TransData Nexus

Wockhardt UK Limited

Pharmaceutical Importer · United Kingdom · Analgesics & Antipyretics Focus · $28.4M Total Trade · DGFT Verified

Wockhardt UK Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $28.4M across 9 products in 7 therapeutic categories. Based on 714 verified import shipments from Indian Customs (DGFT) records, Wockhardt UK Limited is the #1 buyer in 1 product including Codeine. Wockhardt UK Limited sources from 5 verified Indian suppliers, with Wockhardt Limited accounting for 68.9% of imports.

Wockhardt UK Limited — Import Portfolio & Supplier Network

Wockhardt UK Limited import network — 9 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Wockhardt UK Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Wockhardt Limited	$22.9M	632	68.9%
Ind Swift Limited	$5.7M	293	17.2%
Centaur Pharmaceuticals Private Limited

What Formulations Does Wockhardt UK Limited Import?

Formulation	Value	Ships
Co-codamol 30MG/500MG tablets 100 tablets Pack (Each tablets contains 30MG of codeine phosphate and 500MG	$2.1M	43
Co-codamol 30MG/500MG tabs 100 tabs Pack(Each tabs cont.codeine phosphate hemihydrate PH.EUR 30MG & 500MG of	$1.4M	45
Levothyroxine 25 MCG tablet. 28	$767.5K	17
Indian harmless medicine:yaltormin sr	$607.5K	27
Levothyroxine 25 MCG tablet. 28 tablets Pack. Each tablet contains 25 MCG levothyroxine sodium ph. (total	$575.7K	15
Indian harmless medicine:yaltormin sr	$509.8K	33
Co-codamol 30MG/500MG tablets (Each	$450.0K	9
Levothyroxine 25 MCG tablet. 28 tablets Pack Each tablet contains 25mcg levothyroxine sodium ph. (total no	$400.0K	8
Co-codamol 30MG/500MG tablets 30 tablets Pack (Each tablets contains30mg of codeine phosphate and 500MG of	$398.6K	8
Paracetamol 500MG caplet paracetamol 500MG caplet 12x16 bli	$390.7K	10
Ibuprofen 200MG TAB ibuprofen 200MG TAB 12x16 bli	$367.3K	9
Paracetamol ex str tablets. 192	$346.3K	9
Folic acid 5MG TAB folic acid 5MG TAB 28 bli	$309.3K	8
Ibuprofen 200MG caplet 12x16 bli pk	$306.9K	8
Co codamol 30MG 500MG tablets 100 tablets Pack Each tablets contains 30MG of codeine phosphate and 500MG	$300.0K	6

Wockhardt UK Limited imports 567 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 9 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Codeine	Analgesics & Antipyretics	$9.6M	191	8.7%	1
2	Ramipril	Cardiovascular	$6.7M	276	7.4%	2
3	Levothyroxine	Diabetes & Endocrine	$5.2M	103	6.6%	4
4	Ibuprofen	Analgesics & Antipyretics	$2.6M	53	0.5%	2
5	Prednisolone	Respiratory	$2.6M	53	2.8%	2
6	Folic	Nutritional Supplements	$800.0K	16	1.4%	7
7	Tamoxifen	Advanced Oncology	$409.8K	9	2.8%	6
8	Colchicine	Lipid & Metabolism	$338.8K	10	1.6%	9
9	Melatonin	Nutritional Supplements	$150.0K	3	1.6%	3

Wockhardt UK Limited imports 9 pharmaceutical products across 7 categories into United Kingdom totaling $28.4M. The company is the #1 buyer for 1 product: Codeine.

Wockhardt UK Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Wockhardt UK Limited, established on 2 June 2006, is a private limited company headquartered at Ash Road North, Wrexham Industrial Estate, Wrexham, LL13 9UF, United Kingdom. (find-and-update.company-information.service.gov.uk) As a subsidiary of Wockhardt Limited, an Indian multinational pharmaceutical and biotechnology company, Wockhardt UK Limited plays a pivotal role in the UK's pharmaceutical distribution network. The parent company, Wockhardt Limited, is renowned for its research-based approach, offering a diverse portfolio that includes pharmaceuticals, biotechnology products, and vaccines.

In the UK, Wockhardt UK Limited is recognized as a leading supplier of generic and branded medicines, serving both the National Health Service (NHS) and UK grocery retailers. The company has been a trusted partner to the NHS for over 60 years, providing a wide range of products across various therapeutic areas. Their portfolio encompasses over 170 product lines, including critical medicines manufactured both domestically and internationally.

2Distribution Network

Wockhardt UK Limited operates a centralized distribution model from its facility in Wrexham, North Wales. This site serves as the primary hub for the company's operations, encompassing manufacturing, packaging, and inspection processes. The facility is equipped with advanced technologies and adheres to stringent regulatory standards, ensuring the efficient distribution of pharmaceutical products across the United Kingdom.

3Industry Role

Within the UK's pharmaceutical supply chain, Wockhardt UK Limited functions as a primary wholesaler and supplier of generic and branded medicines. The company collaborates closely with the NHS and various healthcare providers to ensure the timely and reliable delivery of essential medications. Their extensive product range and established relationships position them as a key player in the UK's pharmaceutical distribution landscape.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Wockhardt UK Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Wockhardt UK Limited's sourcing strategy exhibits a significant concentration on a select group of suppliers. The company's total import value from India amounts to $28.4 million USD, with 714 shipments covering nine products across seven therapeutic categories. Notably, the top five products—Codeine, Ramipril, Levothyroxine, Ibuprofen, and Prednisolone—account for 94% of the total import value. This high concentration suggests a strategic focus on specific therapeutic areas, potentially leveraging established supplier relationships to ensure consistent product quality and availability.

The dominance of Wockhardt Limited as the primary supplier, accounting for 68.9% of the total import value, indicates a strong and stable partnership. However, the presence of other suppliers, such as Ind Swift Limited and Centaur Pharmaceuticals Private Limited, introduces a level of diversification, which can mitigate risks associated with over-reliance on a single source. This diversified sourcing approach may enhance supply chain resilience and provide flexibility in response to market dynamics.

2Supply Chain Resilience

Wockhardt UK Limited's supply chain demonstrates resilience through its diversified supplier base and the importation of 567 unique pharmaceutical formulations. The inclusion of multiple suppliers, including Wockhardt Limited, Ind Swift Limited, and Centaur Pharmaceuticals Private Limited, reduces dependency on a single source and enhances the company's ability to adapt to supply chain disruptions. Additionally, the company's focus on finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), suggests a streamlined supply chain that may be less susceptible to fluctuations in raw material availability.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) serves as the primary regulatory authority overseeing the safety, efficacy, and quality of pharmaceutical products. The MHRA is responsible for granting marketing authorizations, conducting inspections, and ensuring compliance with established standards.

Key legislation governing pharmaceutical imports into the UK includes the Human Medicines Regulations 2012, which transposes European Union directives into UK law, and the Medicines Act 1968. These regulations outline the requirements for importing, manufacturing, and distributing medicinal products within the UK.

For Indian generics to be marketed in the UK, they must undergo a marketing authorization process, which involves submitting a dossier to the MHRA demonstrating the product's quality, safety, and efficacy. This process may include clinical trials, bioequivalence studies, and compliance with Good Manufacturing Practice (GMP) standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the UK are stringent. Importers must hold a Wholesale Dealer's License issued by the MHRA, which authorizes the distribution of medicinal products. Additionally, imported products must comply with GMP standards recognized by the MHRA, ensuring that manufacturing processes meet quality and safety criteria.

Wockhardt UK Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Wockhardt UK Limited's product strategy focuses on therapeutic areas such as analgesics, cardiovascular, and diabetes & endocrine treatments. The company's import data reveals a significant emphasis on analgesics and antipyretics, accounting for 43.0% of total imports, followed by cardiovascular products at 23.6%, and diabetes & endocrine products at 18.1%.

This strategic focus aligns with market demand, as these therapeutic areas address prevalent health conditions in the UK. By concentrating on these segments, Wockhardt UK Limited aims to meet the needs of healthcare providers and patients, ensuring the availability of essential medications.

2Sourcing Profile

Wockhardt UK Limited's sourcing strategy centers on generic drugs, with a particular emphasis on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. The company's import data indicates a diverse range of formulations, with 567 unique products sourced from India.

India's role as a supplier is integral to Wockhardt UK Limited's procurement strategy, offering a reliable source of high-quality generic medications. The company's established relationships with Indian suppliers, including Wockhardt Limited, Ind Swift Limited, and Centaur Pharmaceuticals Private Limited, facilitate a consistent supply of these formulations.

Market Positioning

Seller's Guide — How to Become a Supplier to Wockhardt UK Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Wockhardt UK Limited's supply chain.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Wockhardt UK Limited

What products does Wockhardt UK Limited import from India?

Wockhardt UK Limited imports 9 pharmaceutical products across 7 categories. Top imports: Codeine ($9.6M), Ramipril ($6.7M), Levothyroxine ($5.2M), Ibuprofen ($2.6M), Prednisolone ($2.6M).

Who supplies pharmaceuticals to Wockhardt UK Limited from India?

Wockhardt UK Limited sources from 5 verified Indian suppliers. The primary supplier is Wockhardt Limited (68.9% of imports, $22.9M).

What is Wockhardt UK Limited's total pharmaceutical import value?

Wockhardt UK Limited's total pharmaceutical import value from India is $28.4M, based on 714 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Wockhardt UK Limited focus on?

Wockhardt UK Limited imports across 7 categories. The largest: Analgesics & Antipyretics (43.0%), Cardiovascular (23.6%), Diabetes & Endocrine (18.1%).

Get Full Wockhardt UK Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.